Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11970985 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Guntermann C, Alexander DR (2002) CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases. J Immunol 168, 4420-9 11970985
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y201-p - CTLA-4 (human)
Orthologous residues
CTLA‑4 (human): Y201‑p, CTLA‑4 (mouse): Y201‑p, CTLA‑4 (rat): Y201‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte), T lymphocyte-blood
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
SHP-1 (human) Induces enzymatic activity, induced, molecular association, regulation pull-down assay, in vitro

Y218-p - CTLA-4 (human)
Orthologous residues
CTLA‑4 (human): Y218‑p, CTLA‑4 (mouse): Y218‑p, CTLA‑4 (rat): Y218‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte), T lymphocyte-blood
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
SHP-1 (human) Induces enzymatic activity, induced, molecular association, regulation pull-down assay, in vitro

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinitrophenol, anti-CD3 increase trinitrophenol (TNP)
anti-CD3 anti-CD3, dinitrophenol CTLA-4 (human) inhibit treatment-induced increase

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinitrophenol, anti-CD3 increase trinitrophenol (TNP)
anti-CD3 anti-CD3, dinitrophenol CTLA-4 (human) inhibit treatment-induced increase

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte), T lymphocyte-blood
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinitrophenol, anti-CD3 increase trinitrophenol (TNP)
anti-CD3 anti-CD3, dinitrophenol CTLA-4 (human) inhibit treatment-induced increase

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte), T lymphocyte-blood
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinitrophenol, anti-CD3 increase trinitrophenol (TNP)
anti-CD3 anti-CD3, dinitrophenol CTLA-4 (human) inhibit treatment-induced increase

Y319-p - ZAP70 (human)
Orthologous residues
ZAP70 (human): Y319‑p, ZAP70 (mouse): Y318‑p, ZAP70 (rat): Y314‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte), T lymphocyte-blood
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinitrophenol, anti-CD3 increase trinitrophenol (TNP)
anti-CD3 anti-CD3, dinitrophenol CTLA-4 (human) inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.